Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Novarock Biotherapeutics Ltd. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units. This distribution indicates that each of the 2 pending matters is being handled by a different examiner in a different specialized unit of the USPTO. The involvement of 2 distinct art units indicates that the company's filings in the biotechnology sector cover different technical classifications requiring different examiner expertise.
AEDER, SEAN E is the busiest examiner for the portfolio, currently holding 1 busiest examiner pending action. With 2 distinct examiners assigned to 2 pending office actions, the workload is spread evenly across the USPTO staff. This lack of concentration means that the company must navigate 2 different individual examination styles simultaneously. Because each examiner is responsible for 1 busiest examiner pending action, no single individual has a dominant influence over the portfolio's current status. Practitioners should prepare for 2 separate prosecution tracks, each governed by the specific standards of 2 distinct art units and the individual preferences of 2 distinct examiners.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AEDER, SEAN E | 1 | 56.9% | +20.0% |
| DIBRINO, MARIANNE | 1 | 42.8% | +42.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18688720 | BISPECIFIC AND TRISPECIFIC BINDING PROTEINS TO PD-L1, CD137, AND/OR TGF-BETA AND USES THEREOF | AEDER, SEAN E | — |
| 18278373 | ANTIBODIES AGAINST CLAUDIN-6 AND USES THEREOF | DIBRINO, MARIANNE | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18688720 | BISPECIFIC AND TRISPECIFIC BINDING PROTEINS TO PD-L1, CD137, AND/OR TGF-BETA AND USES THEREOF | AEDER, SEAN E | 1642 | §112DP | Non-Final OA | — | Pending | Mar 01, 2024 |
| 18278373 | ANTIBODIES AGAINST CLAUDIN-6 AND USES THEREOF | DIBRINO, MARIANNE | 1641 | §112Other | Non-Final OA | — | Pending | Aug 22, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNovarock Biotherapeutics Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Sean E Aeder has the most, with 1 of Novarock Biotherapeutics Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
